Mark J. Ratain to Interleukin-2
This is a "connection" page, showing publications Mark J. Ratain has written about Interleukin-2.
Connection Strength
0.225
-
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res. 2002 Dec; 8(12):3718-27.
Score: 0.051
-
Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol. 1998 Jul; 39(1):63-73.
Score: 0.037
-
Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood. 1998 Jan 15; 91(2):399-405.
Score: 0.036
-
Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. Eur J Cancer. 1997 Jan; 33 Suppl 1:S34-6.
Score: 0.034
-
Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies. Leuk Lymphoma. 1994 Jul; 14(3-4):257-62.
Score: 0.028
-
A phase I study of subcutaneous recombinant interleukin-2 and interferon alfa-2a. Cancer. 1993 Apr 01; 71(7):2371-6.
Score: 0.026
-
Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041). Invest New Drugs. 2004 Jan; 22(1):83-9.
Score: 0.014